OA02.3. Does Survival Among Patients Achieving Pathological Complete Response Differ Between FLOT and CROSS in Oesophageal Adenocarcinoma?

Clicks: 21
ID: 325975
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #105 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Pathological complete response (pCR) after neoadjuvant therapy is associated with favourable prognosis in oesophageal adenocarcinoma, but whether outcomes differ according to treatment modality remains uncertain. This study compared survival among patients achieving pCR following perioperative FLOT chemotherapy versus CROSS chemoradiotherapy. Methods This international multicentre cohort included patients with oesophageal, or Siewert I/II junctional adenocarcinoma treated between 2018 and 2024 who underwent neoadjuvant FLOT or CROSS followed by curative oesophagectomy and achieved ypT0N0. Data were derived from prospectively maintained databases across 14 European high-volume centres. Patients with squamous carcinoma, incomplete pathological response, non-curative surgery, missing key variables, or 90-day mortality were excluded. Overall survival (OS) was the primary endpoint; secondary endpoints included disease-free survival (DFS), recurrence patterns, and nodal-stage–stratified outcomes. Multivariable Cox regression adjusted for demographic, tumour, and operative factors. Kaplan–Meier methods and sensitivity analyses were performed. Results Of 2717 patients, 297 achieved pCR (CROSS 150; FLOT 147). FLOT patients were younger and more frequently clinically node-positive, but postoperative outcomes were similar. On unadjusted analysis, FLOT was associated with improved OS and DFS (both HR 0.32, p<0.001). After adjustment, FLOT remained independently associated with superior OS (HR 0.34, 95% CI 0.16–0.69, p=0.003) and DFS (HR 0.35, 95% CI 0.19–0.62, p<0.001). Recurrence was less frequent (8.8% vs 24.7%), Patterns differed (p<0.001): distant-only relapse predominated after CROSS (70.3%), whereas FLOT showed fewer distant-only recurrences and longer time to recurrence. cN status sub analysis also showed significant survival benefit in cN0–1 disease was and directionally consistent in cN2–3 disease in FLOT arm. Conclusion This is the largest and only study that directly compares pCR Survival between FLOT and CROSS NAT. Among patients achieving pCR, FLOT was associated with improved survival and reduced recurrence compared with CROSS. These findings suggest that the prognostic significance of pCR may vary according to neoadjuvant modality and should be interpreted in the context of treatment strategy.
Reference Key
openalex_W7204002150 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sam Alhayo, Kerry Chou, Sheraz Markar, Ewen Griffiths
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.015
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.015/70760446/doag077.015.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.